Introduction
The healthcare burden from alcohol-related illness has risen dramatically over the last decade. It is estimated that alcoholrelated disease costs the NHS in England £1.7 billion per year. 1 There were in excess of 800,000 alcohol-related admissions to hospital in the year 2007-08, an increase of 69% from 2002. 2 The number of alcohol-related deaths in the UK has increased from 4,023 (6.7 per 100,000 population) in 1992 to 9,031 (13.6 per 100,000) in 2008. 3 The majority of these (4, 764) were attributable to alcoholic liver disease (ALD). ALD encompasses a spectrum of liver injury, from steatosis or fatty liver through to acute alcoholic hepatitis and liver cirrhosis. The Intensive Care National Audit and Research Centre (ICNARC) database estimates that nationally, critical care admissions due to ALD increased from 550 in 1996 to 1,513 in 2005, with an estimated annual expenditure of £14.7 million (based on 2005 NHS costs). 4 The authors admit this is likely to be an underestimate. Patients with cirrhosis who become critically ill have traditionally been viewed as having a universally poor outcome. 5, 6 This systematic review aims to objectively summarise the outcome data for patients with ALD and examine the prognostic value of liver-disease-specific versus physiology-based scoring systems.
Methodology
The medical literature databases Medline and Embase were searched, with a variety of thesaurus and non-thesaurus linked search terms. No date limits were applied. The searches were limited to articles published in English and were performed via the NHS Evidence Health Information Resources library at http://www.evidence.nhs.uk/nhs-evidence-content/journalsand-databases. The search terms can be grouped into three categories according to the main aspects of the review' s primary Mortality of patients with alcoholic liver disease admitted to critical care: a systematic review S Flood, A Bodenham, P Jackson This review examined the burden of alcohol-related liver disease (ALD) in the intensive care unit, which is increasing, and whether scoring systems can assist in judging prognosis. Embase, Medline and internet databases were searched for relevant articles whose quality was then scored using the Centre for Evidence-Based Medicine's (CEBM) critical appraisal tool. Unit mortality of patients with ALD admitted to intensive care in these studies was between 40-50%. In comparison with liver-specific prognostic scoring, physiological scoring systems discriminated better between survivors and nonsurvivors. This is likely to be a reflection of the fact that patients with ALD in intensive care tend to die of multi-organ failure rather than isolated acute liver failure. In addition to searching Medline and Embase, studies were obtained from the System for Information on Grey Literature in Europe (SIGLE) database, Google Scholar, reference lists of previously retrieved articles and personal communication with experts in the field. Abstracts were selected on the basis of six inclusion criteria ( Table 2 ). These criteria ensured that the selected studies remained relevant to the review' s title. Abstracts that met the inclusion criteria were obtained in full text. Full text articles were critically appraised using the Centre for Evidence-Based Medicine' s (CEBM) scoring tool. The CEBM tool was one specifically designed to appraise prognostic studies. It posed seven questions ( Table 3) concerning the methodological rigor with which the study had been conducted and the applicability of the results to everyday practice. The full CEBM tool can be accessed at http://www.cebm.net/index.aspx?o=1157.
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Results
From a total of 273 'hits,' 161 potentially relevant papers were obtained in abstract form. The full text article was sourced in 34 cases where the abstract suggested the study was likely to meet the set inclusion criteria. Following full text review, 13 studies were rejected for not fulfilling the inclusion criteria, leaving a total of 21 articles to be critically appraised (Figure 1 ). Eight of these articles were published only in abstract or poster-presentation form. 7, 9, 14, 15, 17, 19, 20, 22 The 21 studies contained data on a combined cohort of 20,476 patients. Four studies fulfilled all seven domains of the critical appraisal tool, while eight studies had areas of insufficient evidence and nine were deemed to have major flaws ( Table 4 ). The majority of studies did not detail the grounds on which patients had acquired a diagnosis of 'alcohol-related cirrhosis' or 'alcoholic liver disease'. Seven studies 8, 10, 11, 13, 18, 25, 26 set out diagnostic inclusion criteria, requiring that enrolled patients had a diagnosis of ALD based on a combination of histology, imaging and clinical evidence of portal hypertension.
Nineteen studies provided mortality data for patients with ALD admitted to intensive care. In four studies 19, 20, 21, 25 it was not clear whether reported data referred to unit, hospital or alternative time-point mortality. The majority of studies recruited patients with a mixed aetiology of liver disease (with ALD as the largest group) but five studies 4, 14, 16, 18, 23 provided data on ALD patients exclusively. Four studies 12, 16, 21, 25 examined the mortality of patients according to presenting pathology and six studies 12, 16, 18, 19, 20, 25 assessed mortality according to treatment intervention. Six studies examined the relationship between mortality and number of organ system failures 10, 11, 16, 19, 23, 24 while a total of nine articles analysed the ability of different scoring systems to discriminate between survivors and non-survivors.
Discussion Mortality
The primary objective of the review was to collate data estimating the mortality of patients with ALD who required intensive care. The majority of studies measured mortality at a minimum of two time points, ranging from unit mortality to five-year mortality. Unit mortality was the most frequently used outcome measure and rates ranged from 34 to 63%. The wide range of unit mortality probably arises as a result of studies recruiting patient cohorts with differing illness severity. Das 11 reported unit mortality to be 61%, but this study excluded ALD patients with gastrointestinal bleeding or encephalopathy, which as discussed below, have an arguably better prognosis. Mackle' s 16
Review article Inclusion criteria
• Adult patients only.
• The study should be based on patients with a diagnosis of alcoholic liver disease (ALD). In studies with a patient cohort of mixed aetiology liver disease, the largest group should be ALD.
• Patients should have been admitted to intensive care.
• Primary or main outcome measures should include mortality.
• Studies examining outcomes following liver transplantation or specialist intervention such as MARS were excluded.
• The study should be published in English. Abdel (7) 2009 2c 100 Cirrhotic patients requiring mechanical Abstract only ventilation. Excluded elective surgery.
Aggarwal (8) 2001 2c 480 Consecutive patients admitted to a medical Non-UK patient ICU over a four-year period with cirrhosis. population Christensen (9) 2009 2b 279 From 12,097 ICU admissions, 279 patients Abstract only had ALD.
Cholongitis (10) 2006 2c 312 Cirrhotic patients admitted to ICU, 65% Single centre study had alcohol as aetiology. Transplant patients excluded.
Das (11) 2010 2c 138 Patients with cirrhosis requiring medical Patients not requiring ICU in a regional liver transplant centre.
extra-hepatic organ support were excluded Du Cheyron (12) 2005 2b 186 Cirrhotic patients admitted to ICU; Single centre study majority had alcohol as aetiology.
Gildea (13) 2004 2c 422 Consecutive patients admitted to a medical Non UK centre ICU over a four-year period with diagnosis of cirrhosis. Transplant patients excluded Goutcher (14) 2006 2c 63 All patients with ALD admitted to ICU Abstract only over a five-year period Mackay (15) 2010 2c 500 Prospective case note review of Abstract only 500 admissions to ICU.
Mackle (16) 2006 2c 107 Patients with decompensated ALD admitted to general ICU.
McPhail (17) 2011 2c 486 Consecutive patients admitted to ICU Poster presentation with cirrhosis confirmed on histological, radiological or clinical criteria.
Rabe (18) 2004 2c 76 Paitents with liver cirrhosis requiring Only included intubation and ventilation over a patients requiring 10-year period. IPPV Rye (19) 2009 2c 79 Retrospective review of patients with Abstract only alcoholic cirrhosis admitted to general ICU over six-year period. Saliba (20) 2009 2c 308 Consecutive patients with decompensated Abstract only liver disease admitted to ICU over a three-year period.
Singh (21) 1998 2c 40
Patients with cirrhosis who required Specialist admission to ICU while awaiting transplant centre liver transplantation.
Thomson (22) 2010 2c 118 Data collected prospectively on patients Abstract only with cirrhosis admitted to general ICU.
Wehler (23) 2001 2c 143 Consecutive admissions of patients Non UK centre with hepatic cirrhosis who required ICU over a two-year period.
Welch (4) 2008 2c 4219 Secondary anaylsis of the Case Mix Program database (ICNARC) 1995-2005. Multi centre, UK-based study.
Zauner (24) 1999 2b 208 Patients admitted to a general ICU with Non UK centre ALD Zauner (25) 1996 2c study, which scored highly on critical appraisal, estimated overall unit mortality at 56%. This patient cohort was recruited from a university hospital with a regional tertiary referral centre for hepato-biliary disease and the Scottish Liver Transplant Unit. It is likely that patients were more severely ill than those managed in non-transplant centres. Comparing the average admission APACHE II scores from the studies supports this. Mackle' s 16 cohort (unit mortality 56%) had a median APACHE II score of 25 (20-31) while Thomson' s 22 patients (unit mortality 38%) scored a median APACHE II of 16 (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) .
Excluding studies that had methodological flaws on critical appraisal might make a more focussed estimate of mortality. Collating the four studies 8, 13, 22, 23 that scored highest on critical appraisal, fulfilling all seven domains of the appraisal tool, unit mortality is estimated to be between 36 and 44%. Alternatively, data from studies that exclusively recruited ALD patients may be pooled. From the five studies that provide data on ALD patients exclusively, 50% of these patients died in intensive care. The predominant contribution to this data came from Welch et al, 4 who collated the ICNARC data for all admissions with ALD to UK intensive care units over a 10-year period from 1995. They document a slight reduction in mortality from 50% to 43% over the 10-year study period. Their data is based on a large cohort of patients (4,219) across a representative sample of UK units. It therefore seems reasonable to conclude that the unit mortality of patients with ALD admitted to intensive care is between 40-50%. This is higher than the 27% national average unit mortality for critically ill medical patients for the same time period. 27
Presenting features
Patients with ALD commonly require intensive care for combinations of sepsis, hepatic encephalopathy, gastrointestinal bleeding, respiratory failure, spontaneous bacterial peritonitis or acute kidney failure. Four studies 12, 16, 21, 25 estimated the mortality of patients admitted to ICU according to their presenting complication. ALD patients admitted to intensive care with sepsis reportedly have a mortality of 67-88%. The evidence base for this conclusion is very poor. Neither of the two studies involved clearly defined 'sepsis'. Singh' s 21 data is based on only three patients labelled as 'sepsis/hypotension' and it is not clear whether data refers to unit or hospital mortality. Mackle 16 states that 'hospital mortality in the sepsis/multiorgan failure group was 88%' but no further details of inclusion criteria are given in the text. A single study 16 provides mortality data for patients presenting with encephalopathy; Mackle estimates unit, hospital, 6-month and 12-months mortality at 14%, 33%, 60% and 80% respectively. This data suggest that, in the short term at least, patients presenting only with encephalopathy do relatively well and survive to hospital discharge. Their medium-to-long term prognosis appears more guarded, with a 12-month survival of only 20%. However, the data is based on only seven patients, and the authors provide no indication of encephalopathy severity, stating that 'the encephalopathy group were patients who presented with decompensated ALD in the absence of demonstrable sepsis or gastrointestinal haemorrhage.'
The Mackle 16 study is the only one to provide data on patients admitted with gastrointestinal haemorrhage, quoting a mortality of: 48%, 62%, 67% and 68% for unit, hospital, 6-month and 12-month (n=60). This suggests that gastrointestinal haemorrhage requiring intensive care has a significant initial risk of mortality (almost 50%) but that most patients surviving to hospital discharge are still alive at one year. No data was found on the outcome of patients admitted to intensive care with spontaneous bacterial peritonitis. Two studies have examined the prognosis of patients admitted with acute renal failure (ARF). Mackle defines ARF as a serum creatinine >120 μmol/L, quoting a unit mortality of 75% and a hospital mortality of 87% (n=60). Du Cheyron' s 12 paper specifically addresses the attributable mortality of ARF in cirrhotic patients admitted to intensive care. He quotes a mortality of 46% (unit) and 51% (hospital) for mild and 78% (unit) and 84% (hospital) for severe renal failure (n=73). De Cheyron' s definitions of mild and severe are as defined by the Acute Dialysis Quality Initiative group RIFLE classification 28 with mild equating to 'risk' or 'injury' and severe meaning 'failure.' It is difficult to combine Mackle' s and Du Cheyron' s data sets based on differing definitions of ARF. The RIFLE definition is arguably more clinically relevant than an arbitrary creatinine level, which does not take into account the size/build of the patient or their baseline GFR. It is reasonable to speculate that a creatinine >120 μmol/L equates to Du Cheyron' s mild ARF group and that the differing mortality between the two studies relates to admission illness severity (median APACHE II scores: 25 16 vs 20 12 ). There is some evidence 29 that the aetiology of acute kidney injury (sepsis, hypovolaemia, hepatorenal syndrome) in the cirrhotic patient influences outcome. This study is not formally included in this review as it did not recruit patients from critical care exclusively.
Organ support
Three papers provide mortality data according to organ system support. Patients may be categorised as requiring intermittent positive pressure ventilation (IPPV), vasoactive drugs and/or renal replacement therapy (RRT). Mackle 16 reports mortality figures for all three groups while Saliba 20 and Rye 19 discuss vasoactive infusions and RRT respectively. The Mackle data suggest that in general the outcome of patients with ALD who require invasive ventilation is poor, with 72% of all ALD patients on IPPV dying before hospital discharge. The authors also examined the subgroup of patients who required IPPV as a single system support and report a much lower mortality rate. Only 4% of patients requiring IPPV alone died in ICU and 69% survived to hospital discharge. The requirement for any additional organ support places patients in a much higher risk group (IPPV + vasoactive drugs: hospital mortality 80%, IPPV + RRT: hospital mortality 83%). 16 The outcome of patients with ALD requiring vasoactive drugs by continuous infusion is generally poor, with a unit mortality of 74-81% and a hospital mortality of 86%. 16, 20 Studies did not clearly differentiate between inotropes and vasopressors or comment on the outcome of patients receiving only terlipressin. The need for renal replacement therapy is associated with the greatest risk of death, with Mackle and Saliba quoting a hospital mortality approaching 90%. Rye 19 found 100% mortality among patients requiring RRT. None of the three studies detailed the indications for RRT.
Number of organ system failures
The relationship between patient outcome and their number of organ system failures is relatively consistent between studies. A total of six papers 10, 11, 16, 19, 23, 24 contributed to the data, three of which scored highly on critical appraisal. 16, 19, 23 Mortality rates ranged from 33-45% for single organ system failure, 65-75% for two organ system failures and 90-100% for three system failures. The data clearly suggest that a patient' s chance of recovery decreases significantly with each additional system failure and that three system failures is associated with a very poor prognosis. Das found that with the exception of haematological failure, all other organ system failures including cardiovascular, respiratory, renal, hepatic and neurological failure were significant risk factors for in-hospital mortality. 11
Prognostic value of scoring systems
The Child and Turcotte classification was first published in 1964 before being modified by Pugh in 1973 as the Child-(Turcotte)-Pugh Score (CPS). It was developed to assess the risk of death in patients with chronic liver disease undergoing porto-systemic shunting or oesophageal transection procedures. The modified score consists of five components: bilirubin, albumin, prothrombin time, severity of ascites, and encephalopathy. The Model for End-stage Liver Disease (MELD) is a more recently developed score used to predict short-term survival in cirrhotic patients and prioritise transplant lists. The Acute Physiology And Chronic Health Evaluation (APACHE) score and Sequential Organ Failure Assessment (SOFA) tools are based on acute physiological parameters and are familiar to those working in intensive care.
Nine studies compared the prognostic value of liver-specific and physiology-based scoring systems in patients with ALD admitted to intensive care. The size of the study cohorts ranged from 76 to 486, with a total of 1,742 patients across all nine studies. Mean ages ranged from 50-55 years. The commonest primary reason for admission was gastrointestinal haemorrhage, followed by hepatic encephalopathy. Other common reasons included sepsis and ARF. The ability of prognostic models to differentiate between survivors and nonsurvivors was tested in all nine studies by examining the area under the curve (AUC) of Receiver Operator Characteristic (ROC) curves. Seven out of the nine papers compared liverspecific scores against acute physiological scores and six found the physiology-based systems more discriminating. SOFA performed the best, with the majority of studies calculating an AUC >0.90. When Das compared modified (to exclude haematological failure) SOFA scores taken on days 1 and 3, he found the latter significantly more discriminating. With the exception of Rabe 18 who rated CPS above APACHE II, the remaining eight studies rated CPS the weakest discriminator, with AUC ranging from 0.61 to 0.75. Many patients requiring admission to intensive care are CPS grade C and this may explain its inability to discriminate between survivors and nonsurvivors. Most studies scored MELD and APACHE II as moderately discriminating, with MELD achieving an AUC of 0.81 in three quarters of studies and APACHE II ranging from 0.66 to 0.90. Two studies generated novel scoring systems. 17, 26 The ability of the acute physiology scores to discriminate between survivors and non-survivors better is likely to be a reflection of the fact that patients with ALD in critical care tend to die of multi-organ failure rather than isolated acute liver failure. Das found that the severity of underlying liver disease was not a predictor of hospital mortality in patients with ALD admitted to intensive care. 11 The liver-specific scores, which focus on markers of hepatic function such as INR and albumin, are unsurprisingly insensitive to distant organ failures. MELD probably prognosticates better than CPS as it includes creatinine and will therefore detect acute kidney injury.
Limitations of the analysis
This review systematically searched two medical literature databases, with a variety of search terms and without date limitations. It strived to obtain other relevant publications from grey literature sources, reference lists of previously obtained articles and unpublished data via personal communication.
The main limitations are that searching was restricted to the English language only, and that articles were selected and critically appraised by a single investigator (SF). Eight of the final twenty-one studies accepted for inclusion were published in abstract or poster form only. The inclusion criteria for the review included a requirement that alcohol was the single or dominant liver disease aetiology in the study population. This may have led to the exclusion of some mixed aetiology studies that selectively reported mortality data on ALD patients as a minority group.
Conclusion
There are no randomised trials examining the role of intensive care or invasive organ support in patients with ALD. The evidence for outcomes in this population of patients comes from a relatively small number of largely retrospective observational studies. The average unit mortality of patients with ALD admitted to intensive care is higher than the average non-surgical intensive care population, at 40-50%. Some subgroups of ALD patients have a better prognosis than others and mortality varies with presenting complication, treatment intervention required and number of organ system failures.
Patients admitted with encephalopathy or those requiring single organ respiratory support have a unit mortality lower than the general non-surgical ICU population. Fewer than a third of patients presenting with acute kidney injury or requiring vasoactive infusions survive intensive care. Patients requiring renal replacement therapy have an over-80% average mortality, while those with three or more system failures consistently have a mortality rate greater than 90%. Acute physiology based scoring systems more closely predict mortality than traditional liver-specific scores; three-quarters of studies found that the SOFA score was the optimal tool for discriminating between survivors and non-survivors.
Patients admitted to intensive care with ALD have a wide spectrum of outcomes. We suggest that the data summarised in this review supports a pragmatic approach to this patient cohort. In deciding whether a patient is likely to benefit from invasive organ support, clinicians should avoid being unduly influenced by the severity of the underlying liver disease but be guided by the number, severity and apparent reversibility of non-haematological organ system failures. A trial of therapy with sequential SOFA scoring over two or three days allows those patients that are going to benefit to do so, while providing clarity to clinicians (and families) in those cases where the outlook is bleak that ongoing invasive support is not beneficial and a palliative approach more appropriate.
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